Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Chemical Biology Consortium Sweden, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Karolinska Institutet, Stockholm, Sweden.
PLoS One. 2018 Apr 23;13(4):e0195956. doi: 10.1371/journal.pone.0195956. eCollection 2018.
Tenovin-6 is the most studied member of a family of small molecules with antitumour activity in vivo. Previously, it has been determined that part of the effects of tenovin-6 associate with its ability to inhibit SirT1 and activate p53. However, tenovin-6 has also been shown to modulate autophagic flux. Here we show that blockage of autophagic flux occurs in a variety of cell lines in response to certain tenovins, that autophagy blockage occurs regardless of the effect of tenovins on SirT1 or p53, and that this blockage is dependent on the aliphatic tertiary amine side chain of these molecules. Additionally, we evaluate the contribution of this tertiary amine to the elimination of proliferating melanoma cells in culture. We also demonstrate that the presence of the tertiary amine is sufficient to lead to death of tumour cells arrested in G1 phase following vemurafenib treatment. We conclude that blockage of autophagic flux by tenovins is necessary to eliminate melanoma cells that survive B-Raf inhibition and achieve total tumour cell kill and that autophagy blockage can be achieved at a lower concentration than by chloroquine. This observation is of great relevance as relapse and resistance are frequently observed in cancer patients treated with B-Raf inhibitors.
Tenovin-6 是具有体内抗肿瘤活性的小分子家族中研究最多的成员。先前已经确定,Tenovin-6 的部分作用与其抑制 SirT1 和激活 p53 的能力有关。然而,Tenovin-6 也被证明可以调节自噬通量。在这里,我们表明,在多种细胞系中,某些 Tenovins 会引起自噬通量阻断,无论 Tenovins 对 SirT1 或 p53 的作用如何,自噬阻断都会发生,并且这种阻断依赖于这些分子的脂肪叔胺侧链。此外,我们评估了这种叔胺在体外消除增殖性黑素瘤细胞中的作用。我们还证明,在vemurafenib 治疗后,存在叔胺足以导致 G1 期停滞的肿瘤细胞死亡。我们得出结论,Tenovins 阻断自噬通量对于消除存活的 B-Raf 抑制剂的黑素瘤细胞并实现完全肿瘤细胞杀伤是必要的,并且自噬阻断可以在比氯喹更低的浓度下实现。这一观察结果非常重要,因为在接受 B-Raf 抑制剂治疗的癌症患者中经常观察到复发和耐药。